Compare PIII & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PIII | EVGN |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | Israel |
| Employees | 360 | N/A |
| Industry | Medical/Nursing Services | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 9.1M |
| IPO Year | N/A | 2013 |
| Metric | PIII | EVGN |
|---|---|---|
| Price | $2.82 | $0.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $16.25 | $3.50 |
| AVG Volume (30 Days) | 100.9K | ★ 131.3K |
| Earning Date | 03-26-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | $73.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.73 |
| 52 Week High | $11.30 | $2.42 |
| Indicator | PIII | EVGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.47 | 45.08 |
| Support Level | $1.52 | $0.81 |
| Resistance Level | $2.85 | $1.23 |
| Average True Range (ATR) | 0.53 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 30.81 | 56.57 |
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.